Pfizer's dual-acting combination therapy of Clesacostat tromethamine and Ervogastat targets ACC and DGAT2 for treating metabolic dysfunction-associated steatohepatitis (MASH) with liver fibrosis.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.